User menu

Pharmacogenetic-based strategy using de novo tacrolimus once daily after kidney transplantation: prospective pilot study.

Bibliographic reference De Meyer, Martine ; Haufroid, Vincent ; Kanaan, Nada ; Darius, Tom ; Buemi, Antoine ; et. al. Pharmacogenetic-based strategy using de novo tacrolimus once daily after kidney transplantation: prospective pilot study.. In: Pharmacogenomics, Vol. 17, no.9, p. 1019-1027 (2016)
Permanent URL http://hdl.handle.net/2078.1/175853
  1. Kuypers Dirk R.J., Peeters Patrick C., Sennesael Jacques J., Kianda Mireille N., Vrijens Bernard, Kristanto Paulus, Dobbels Fabienne, Vanrenterghem Yves, Kanaan Nada, Improved Adherence to Tacrolimus Once-Daily Formulation in Renal Recipients : A Randomized Controlled Trial Using Electronic Monitoring, 10.1097/tp.0b013e3182725532
  2. Stifft Frank, Stolk Leo M.L., Undre Nasrullah, van Hooff Johannes P., Christiaans Maarten H.L., Lower Variability in 24-Hour Exposure During Once-Daily Compared to Twice-Daily Tacrolimus Formulation in Kidney Transplantation : , 10.1097/01.tp.0000437561.31212.0e
  3. van Hooff Johannes P., Alloway Rita R., Trunečka Pavel, Mourad Michel, Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies : Four-yr experience with Tacrolimus QD, 10.1111/j.1399-0012.2010.01377.x
  4. Krämer B. K., Charpentier B., Bäckman L., Silva Jr H. Tedesco, Mondragon-Ramirez G., Cassuto-Viguier E., Mourad G., Sola R., Rigotti P., Mirete J. Ortuno, , Tacrolimus Once Daily (ADVAGRAF) Versus Twice Daily (PROGRAF) in De Novo Renal Transplantation: A Randomized Phase III Study : Tacrolimus QD/BID in de novo Renal Transplantation, 10.1111/j.1600-6143.2010.03256.x
  5. Kitada Hidehisa, , Okabe Yasuhiro, Nishiki Takehiro, Miura Yoshifumi, Kurihara Kei, Terasaka Soushi, Kawanami Sayako, Tuchimoto Akihiro, Masutani Kohsuke, Tanaka Masao, One-Year Follow-Up of Treatment With Once-Daily Tacrolimus in De Novo Renal Transplant, 10.6002/ect.2012.0087
  6. Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, Vinks AA, He Y, Swen JJ, Leeder JS, van Schaik RHN, Thummel KE, Klein TE, Caudle KE, MacPhee IAM, Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines forCYP3A5Genotype and Tacrolimus Dosing, 10.1002/cpt.113
  7. Haufroid V., Wallemacq P., VanKerckhove V., Elens L., De Meyer M., Eddour D. C., Malaise J., Lison D., Mourad M., CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study, 10.1111/j.1600-6143.2006.01518.x
  8. Elens Laure, Hesselink Dennis A., van Schaik Ron H. N., van Gelder Teun, Pharmacogenetics in Kidney Transplantation : Recent Updates and Potential Clinical Applications, 10.1007/s40291-012-0012-5
  9. Hesselink Dennis A, Bouamar Rachida, van Gelder Teun, The Pharmacogenetics of Calcineurin Inhibitor–Related Nephrotoxicity : , 10.1097/ftd.0b013e3181e44244
  10. Barraclough Katherine A., Isbel Nicole M., Johnson David W., Campbell Scott B., Staatz Christine E., Once- Versus Twice-Daily Tacrolimus : Are the Formulations Truly Equivalent?, 10.2165/11593890-000000000-00000
  11. Wlodarczyk Zbigniew, Ostrowski Marek, Mourad Michel, Krämer Bernhard K., Abramowicz Daniel, Oppenheimer Federico, Miller Derek, Dickinson James, Undre Nasrullah, Tacrolimus Pharmacokinetics of Once- Versus Twice-Daily Formulations in De Novo Kidney Transplantation : A Substudy of a Randomized Phase III Trial., 10.1097/ftd.0b013e31824d1620
  12. Alloway R., Steinberg S., Khalil K., Gourishankar S., Miller J., Norman D., Hariharan S., Pirsch J., Matas A., Zaltzman J., Wisemandle K., Fitzsimmons W., First M.R., Conversion of Stable Kidney Transplant Recipients From a Twice Daily Prograf-Based Regimen to a Once Daily Modified Release Tacrolimus-Based Regimen, 10.1016/j.transproceed.2004.12.222
  13. Staatz Christine E, Tett Susan E, Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation : , 10.2165/00003088-200443100-00001
  14. Macphee Iain A. M., Fredericks Salim, Tai Tracy, Syrris Petros, Carter Nicholas D., Johnston Atholl, Goldberg Lawrence, Holt David W., Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirement : , 10.1097/00007890-200212150-00002
  15. Hesselink D, Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus, 10.1016/s0009-9236(03)00168-1
  16. Haufroid Vincent, Mourad Michel, Van Kerckhove Val??rie, Wawrzyniak Jeremie, De Meyer Martine, Eddour Djamila Chaib, Malaise Jacques, Lison Dominique, Squifflet Jean-Paul, Wallemacq Pierre, The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients : , 10.1097/00008571-200403000-00002
  17. Thervet E, Clin. Pharmacol. Ther., 87, 721 (2010)
  18. Wehland M, Pharmacogenet. Genomics, 21, 179 (2011)
  19. Ekberg Henrik, Tedesco-Silva Helio, Demirbas Alper, Vítko Štefan, Nashan Björn, Gürkan Alp, Margreiter Raimund, Hugo Christian, Grinyó Josep M., Frei Ulrich, Vanrenterghem Yves, Daloze Pierre, Halloran Philip F., Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation, 10.1056/nejmoa067411
  20. Audard V, Transpl. Int., 21, 11 (2008)
  21. Heisel Olaf, Heisel Rochelle, Balshaw Robert, Keown Paul, New Onset Diabetes Mellitus in Patients Receiving Calcineurin Inhibitors: A Systematic Review and Meta-Analysis, 10.1046/j.1600-6143.2003.00372.x
  22. Uchida J., Iwai T., Kabei K., Machida Y., Kuwabara N., Naganuma T., Kumada N., Nakatani T., Effects of Conversion From a Twice-Daily Tacrolimus to a Once-Daily Tacrolimus on Glucose Metabolism in Stable Kidney Transplant Recipients, 10.1016/j.transproceed.2013.11.146
  23. Rojas L, Neumann I, Herrero M José, Bosó V, Reig J, Poveda J Luis, Megías J, Bea S, Aliño S F, Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies, 10.1038/tpj.2014.38
  24. Mourad Michel, Wallemacq Pierre, De Meyer Martine, Brandt Dimitri, Van Kerkhove Valérie, Malaise Jacques, Chaïb Eddour Djamila, Lison Dominique, Haufroid Vincent, The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function, 10.1515/cclm.2006.229
  25. Elens L., Bouamar R., Hesselink D. A., Haufroid V., van der Heiden I. P., van Gelder T., van Schaik R. H. N., A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients, 10.1373/clinchem.2011.165613
  26. Elens Laure, van Schaik Ron H, Panin Nadtha, de Meyer Martine, Wallemacq Pierre, Lison Dominique, Mourad Michel, Haufroid Vincent, Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients, 10.2217/pgs.11.90
  27. Pallet N., Jannot A.-S., El Bahri M., Etienne I., Buchler M., de Ligny B. H., Choukroun G., Colosio C., Thierry A., Vigneau C., Moulin B., Le Meur Y., Heng A.-E., Subra J.-F., Legendre C., Beaune P., Alberti C., Loriot M. A., Thervet E., Kidney Transplant Recipients Carrying theCYP3A4*22Allelic Variant Have Reduced Tacrolimus Clearance and Often Reach Supratherapeutic Tacrolimus Concentrations : CYP3A4*22and Tacrolimus, 10.1111/ajt.13059
  28. de Jonge Hylke, Metalidis Christoph, Naesens Maarten, Lambrechts Diether, Kuypers Dirk RJ, The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients, 10.2217/pgs.11.77